Papers In Press, published online ahead of print September 5, 2001
J. Biol. Chem, 10.1074/jbc.M106806200
Submitted on July 19, 2001
Revised on August 28, 2001
Accepted on September 5, 2001
Expression of a mutant form of Leishmania donovani centrin reduces the growth of the parasite
Angamuthu Selvapandiyan, Robert Duncan, Alain Debrabant, Sylvie Bertholet, Gannavaram Sreenivas, Narender S. Negi, Poonam Salotra, and Hira L. Nakhasi
DETTD/OBRR/CBER, FDA, Bethesda, MD 20892
Corresponding Author: Nakhasi{at}cber.fda.gov
Leishmania donovani, a protozoan parasite, causes visceral disease in humans. In order to identify genes that control growth, we have isolated for the first time in the order Kinetoplastida a gene encoding for centrin from L. donovani. Centrin is a calcium binding cytoskeletal protein essential for centrosome duplication or segregation. Protein sequence similarity and immunoreactivity confirmed that Leishmania centrin is a homolog of human centrin 2. Immunofluorescence analysis localized the protein in the basal body. Calcium binding analysis revealed that its C-terminal Ca2+ binding domain binds 16 fold more calcium than the N-terminal domain. Electrophoretic mobility shift of centrin treated with EGTA and abrogation of the shift in its mutants lacking a Ca2+ binding site suggest that Ca2+ binding to these regions may have a role in the protein conformation. The levels of centrin mRNA and protein were high during the exponential growth of the parasite in culture and declined to a low level in the stationary phase. Expression of N-terminal deleted centrin in the parasite significantly reduces its growth rate and it was found that significantly more cells are arrested in the G2/M stage than in control cells. These studies indicate that centrin may have a functional role in Leishmania growth.